Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals gained 1.450% today.
The stock is one of the favorites of our community with 22 Buy predictions and 1 Sell predictions.
With a target price of 32 € there is potential for a 104.93% increase which would mean more than doubling the current price of 15.62 € for Acadia Pharmaceuticals.
Our community identified positive and negative aspects for Acadia Pharmaceuticals stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Acadia Pharmaceuticals stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Acadia Pharmaceuticals | 1.450% | -1.731% | -7.604% | -19.510% | -45.018% | -8.764% | -33.849% |
Novocure Ltd | 1.610% | 4.053% | -18.355% | -80.257% | -17.268% | -93.030% | - |
Sage Therapeutics Inc. | 2.860% | 2.037% | -26.580% | -70.428% | -36.125% | -80.292% | - |
Iovance Biotherapeutics Inc. | 3.910% | 2.211% | -20.519% | 112.456% | 39.152% | -58.641% | - |
Comments
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $37.00 price target on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $25.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat